Schalal Habib
Founder & CEO
San Francisco, United States
Founder kept without complete enrichment
Kos
KOS AI provides Argus, a wrist‑worn, non‑invasive glucose monitor that uses multi‑wavelength photoplethysmography and deep‑learning algorithms to deliver continuous, clinically accurate blood‑glucose readings. The device streams real‑time data to a cloud platform that offers trend analytics, hypo/hyper‑glycemia alerts, and a virtual‑care dashboard for clinicians to manage patients remotely. Revenue is generated from device sales and subscription fees for the analytics and telehealth services.
- Artificial Intelligence
- Digital Health
- Healthcare Technology
- Software Only
Updated 6 months ago
Funding
Raised to date
$100MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
across 1 round
$100M · Undisclosed
Announced Feb 2023
Disclosed cumulative: $100M
RoundDateAmountValuationInvestors
Founders
Product
Problem
People with diabetes must perform frequent finger‑prick tests to obtain glucose readings, which are painful, intermittent, and inconvenient. Traditional glucose monitoring also provides limited data continuity, making it harder for clinicians to track trends and adjust treatment in real time. Healthcare organizations face additional workflow challenges in managing device data and coordinating virtual care appointments.
Solution
KOS AI offers a wrist‑worn, non‑invasive glucose monitoring device called Argus that captures blood‑glucose information through optical sensing rather than needle‑based methods. The device uses multi‑wavelength photoplethysmography combined with custom deep‑learning algorithms to translate subtle light‑absorption changes into accurate glucose readings. Continuous, real‑time data are streamed to a cloud platform that connects patients with virtual healthcare providers, enabling remote monitoring, appointment scheduling, and device management. By eliminating finger pricks and providing ongoing glucose trends, Argus reduces user discomfort, improves adherence, and supports more proactive diabetes care. The platform is designed for both consumer use and integration into clinical workflows, aiming to lower overall care costs while enhancing patient engagement.
Target Audience
Individuals with diabetes seeking painless, continuous glucose monitoring, and healthcare providers (clinics, hospitals, telehealth services) that require remote patient data and streamlined care workflows.
Features
- Multi‑wavelength photoplethysmography (PPG) optical sensors for non‑invasive glucose detection
- Proprietary deep‑learning models that translate optical signals into clinically accurate glucose values
- Continuous real‑time glucose monitoring with on‑device display and cloud sync
- Trend analysis and alerts for hypo‑ and hyper‑glycemia events
- Integrated virtual‑care dashboard for clinicians to view patient data, schedule appointments, and manage devices
- Wearable wrist‑form factor for comfortable, everyday use
- Ongoing clinical trial validation and Clarke Error Grid analysis to confirm accuracy
- Planned consumer launch (Q3 2025) and separate healthcare‑provider version (late 2025)